| Bid | 17.2 |
| Market Cap | 467.93M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.33 |
| PE Ratio (ttm) | -7.41 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 17.36 |
| Volume | 91,648 |
| Avg. Volume (20D) | 408,422 |
| Open | 17.12 |
| Previous Close | 16.59 |
| Day's Range | 16.92 - 17.95 |
| 52-Week Range | 14.30 - 45.00 |
| Beta | undefined |
About ARCT
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as we...
Analyst Forecast
According to 6 analyst ratings, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is $63, which is an increase of 264.69% from the latest price.
Next Earnings Release
Analysts project revenue of $45.92M, reflecting a 35.10% YoY growth and earnings per share of -0.51, making a 59.38% increase YoY.
1 month ago · businesswire.com
Arcturus Therapeutics to Present at Jefferies London Healthcare ConferenceSAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...
2 months ago · seekingalpha.com
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim DataInterim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to re...
2 months ago · seekingalpha.com
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call TranscriptArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joseph...
